Showing results (71-80 of 81) with videos related to

Sort By:
Pageof 9
Cancer Chemotherapy and Pharmacology|January 22, 2025
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)Anuradha Krishnamurthy, Hong Wang, John C Rhee, et al.
The Journal of Clinical Investigation|June 29, 2018
ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiationFrank P Vendetti, Pooja Karukonda, David A Clump, et al.
Cancer Immunology Research|June 27, 2019
IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor CellLulu Shao, Weizhou Hou, Nicole E Scharping, et al.
Cell Reports|September 21, 2022
Thymidine rescues ATR kinase inhibitor-induced deoxyuridine contamination in genomic DNA, cell death, and interferon-α/β expressionNorie Sugitani, Frank P Vendetti, Andrew J Cipriano, et al.
Biorxiv : the Preprint Server for Biology|June 17, 2024
Deoxyuridine-rich cytoplasmic DNA antagonizes STING-dependent innate immune responses and sensitizes resistant tumors to anti-PD-L1 therapyPinakin Pandya, Frank P Vendetti, Joseph El-Ghoubaira, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
ATR kinase inhibitors induce mitochondrial fission in CD8 + T cells and impair immune memory in vivoFrank P Vendetti, Carina R Sclafani, Yunqi Zhang, et al.
Gynecologic Oncology|August 28, 2023
Metronomic dosing of ovarian cancer cells with the ATR inhibitor AZD6738 leads to loss of CDC25A expression and resistance to ATRi treatmentWei Ao, Hong Im Kim, Domenic Tommarello, et al.
Neuro-Oncology|June 7, 2025
Nuclear cholesterol regulates nuclear size and DNA damage responses in cancer stem cellsTingting Duan, Suchet Taori, Shruti Bhargava, et al.
Biorxiv : the Preprint Server for Biology|February 20, 2025
CDKN2A Low cancer cells outcompete macrophages for microenvironmental zinc to drive immunotherapy resistanceRaquel Buj, Aidan R Cole, Jeff Danielson, et al.
Cancer|October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.
Pageof 9